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Numerous reports show the value of plasma measurements 
of the B-type natriuretic peptide (BNP) or N-terminal pro-
BNP (NT-proBNP) to assist in the diagnosis of symptomatic 
heart failure (HF) and to provide independent prediction of 
death and later cardiovascular events in both acute and chronic 
HF.
1)2) And, NPs (BNP and NT-proBNP) are strong predic-
tors of adverse events in acute coronary syndrome.
3) Recent 
studies have shown that obese and overweight individuals 
have considerably lower circulating natriuretic peptide levels 
compared with individuals that have a normal body mass in-
dex (BMI).
4) Also, the serum BNP level changes dynamically 
after the onset of an acute myocardial infarction (AMI). Al-
teration of the BNP level can show a biphasic peak pattern 
for one month after the onset of an AMI.
5) Choi et al.
6) ad-
dressed the relationship between obesity and NT-proBNP 
levels as a prognostic value after AMI.
7) Many variables, such 
as age, sex, renal diseases and their related drug therapies, as 
well as assay methods have been found to affect or confound 
the interpretation of blood NP concentrations.
1) In this study, 
we faced 2 problems for analyzing NP levels, obesity and 
AMI. 
Low Levels of Natriuretic  
Peptides in Obesity
Circulating levels of NPs are significantly lower in over-
weight and obese patients compared with lean patients.
8) There 
are several potential mechanisms responsible for the inverse 
association between NPs and BMI.
1)4) Although the reason for 
the relationship is unknown, the increased concentration of the 
NP clearance receptor on adipocyte cells may suggest that in-
creased clearance is the reason for lower NP levels in obese pa-
tients. Another possibility is that impaired synthesis and release 
of NPs from myocytes in obese subjects must have a role in 
the mechanisms underlying their reduced circulating levels. Also, 
a molecule produced in the lean mass and possibly mediated 
by sex steroid hormones (possibly androgens) may suppress ei-
ther synthesis or release of NPs from cardiomyocytes. This 
study showed that obese patients tend to have lower plasma 
NP concentrations compared to non-obese patients. Howev-
er, additional analysis is required to confirm these results. 
First, in order to analyze diagnostic and prognostic capabili-
ties for NP-proBNP, age-specific consideration was necessary 
as NT-proBNP levels vary for diagnosing HF in patients with 
acute breathlessness. Second, to determine if NT-proBNP was 
equally useful across all BMI categories, affecting variables 
such as age, sex and renal function would have to be adjusted 
in Cox analysis. Third, optimal cut points of NPs for major ad-
verse cardiac event by receiver operating characteristic anal-
ysis for prognosis would be necessary.
B-Type Natriuretic Peptide  
in Acute Myocardial Infarction
 
An elevated serum BNP level after the onset of an AMI can 
be used not only as an independent risk factor but also as a pre-
dictive marker of left ventricular (LV) remodeling.
9) However, 
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NP variation depending on measurement time after myocar-
dial infarction needs to be considered. Maisel et al.
10) showed 
that NP levels might seem discordantly low in patients pre-
senting early with HF symptoms that developed rapidly, in 
under approximately 1-2 hour. In these conditions, BNP gene 
expression has insufficient time between the initial trigger of 
increased ventricular wall stress and the measurement of NP 
levels to up-regulate peptide production. In addition, the ideal 
time for serum NP sampling has been subject to debate as the 
changing pattern of BNP levels in patients with AMI is high-
ly dynamic. The first peak level of BNP develops 20 hours af-
ter AMI onset, and the second peak level presents on approxi-
mately the fifth day. This second peak level of NPs might re-
flect the degree of LV remodeling after index MI. Our study 
addressed the changing patterns of BNP, demonstrating the 
biphasic elevation during early and long-term phase. The ear-
ly phase serum BNP level measured from 2 to 6 days after the 
onset of an AMI, and not at admission, is an independent pre-
dictor for LV remodeling as shown by this long-term follow-
up study.
11) 
In this study, NT-proBNP was measured on arrival. As men-
tioned above, in case of early arrival after onset of AMI, it is 
possible not to increase NT- proBNP levels. In addition, it is 
important to consider infarction size or location because the 
trigger for increased ventricular wall stress was much higher 
for a large myocardial infarction or anterior wall infarction 
than for a small infarction or non-anterior wall. However, 
this study
6) did not show the extent of infarction or location 
distribution in study groups. Therefore, a selection bias when 
enrolling patients into study groups was likely.
In conclusion, in case of analyzing NPs as a prognostic mar-
ker in AMI, it is important to consider BMI as well as age, sex 
and renal function. Also, several associated factors such as 
sample time or infarction size and location confound the ef-
fects of NPs as prognostic factors since their levels are highly 
dynamic depending on the associated factors. 
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